Hisamitsu Pharmaceutical (4530 JT) founding family seeks USD 2.9bln privatisation of the Co, according to Bloomberg

Hisamitsu Pharmaceutical's founding family's bid for a $2.9 billion privatization could signal a strategic shift, potentially affecting the company's governance and operational focus.

Newsquawk StaffNewswiresPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

US President Trump is scheduled to deliver remarks at a GOP member retreat at 10:00EST/15:00GMT on Tuesday and will participate in a policy meeting at 14.30EST/19:30GMT on Tuesday

Eisai (4523 JT) and Biogen (BIIB) announced Eisai and Biogen announce biologics licence application for subcutaneous formulation of LEQEMBI for treating early Alzheimer's disease was accepted in China

Hisamitsu Pharmaceutical (4530 JT) founding family seeks USD 2.9bln privatisation of the Co, according to Bloomberg

[MARKET UPDATE] Copper futures extend on their recent rally with CME futures climbing above the USD 6/lb level, while the benchmark LME copper contract rose to a fresh record high north of USD 13,150/ton

PRE-MARKET CHINESE STOCKS NEWS: Air China (753 HK) is to sell a 1.6% stake in Cathay Pacific (293 HK) for USD 170mln

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Market participants may consider the premium relative to the unaffected share price and any regulatory hurdles that might arise, which could influence investor sentiment towards similar firms in the sector.

Related headlines

The whole workspace, free to try.

Try it free